Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)

NCT02587325 is registered in ClinicalTrials.gov with Aadi Bioscience, Inc. as lead sponsor.

NCT NCT02587325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02587325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Aadi Bioscience, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2017
Completion date
September 16, 2022
Enrollment
15 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension